Assoc Prof Dr. Mohd. FarooqShaikh | Pharmacology | Excellence in Research
Assoc Prof Dr. Mohd. FarooqShaikh, Charles Sturt University, Australia
Assoc Prof Dr. Mohd. Farooq Shaikh is an accomplished academic and researcher with expertise in pharmacology. Currently serving as Associate Professor and Head of Pharmacy Discipline at Charles Sturt University, Australia, he also holds positions as Adjunct Associate Professor at MONASH University Malaysia and Adjunct Senior Research Fellow at MONASH University, Australia. With over a decade of teaching experience, he has contributed significantly to medical education, research, and leadership roles. Dr. Shaikh earned his PhD in Pharmacology from the University of Mumbai and holds a Graduate Certificate in Higher Education from Monash University. Passionate about neuropharmacology, he has led research initiatives and supervised higher degree research. 🎓🔬
Publication Profile:
Education:
Dr. Mohd. Farooq Shaikh’s academic journey reflects a commitment to excellence in pharmacology and education. In 2012, he earned his PhD in Pharmacology from the Institute of Chemical Technology, University of Mumbai, India, delving into the pharmacological evaluation of Eclipta alba in experimental models of epilepsy. His pursuit of knowledge continued with an M. Pharm. in Pharmacology from Rajiv Gandhi University of Health Sciences in 2007, followed by a B. Pharm. degree in 2004. Demonstrating his dedication to teaching, he completed a Graduate Certificate in Higher Education (GCHE) at Monash University, Malaysia, in 2018. Dr. Shaikh’s diverse educational background underpins his expertise in the field. 📚💊
Professional Experience:
Dr. Mohd. Farooq Shaikh, an accomplished academic, currently serves as Associate Professor and Head of Pharmacy Discipline at Charles Sturt University, Australia. Simultaneously, he holds the role of Adjunct Associate Professor at MONASH University Malaysia and Adjunct Senior Research Fellow at MONASH University, Australia. With a rich teaching history spanning over a decade, he has been pivotal in various capacities, including as a Senior Lecturer and Coordinator of the Pharmacology Discipline in MBBS/MD programs. Dr. Shaikh’s international exposure includes a fellowship at the University of Queensland, where he explored the anticonvulsant activity of Luteolin in epilepsy models. His four-year PhD journey focused on the pharmacological evaluation of Eclipta alba in epilepsy models. 🌐👨🏫
Awards:
Dr. Mohd. Farooq Shaikh’s exceptional contributions have earned him numerous accolades, showcasing his prowess in research and mentorship. In 2022, he clinched the Monash University Postgraduate Association (MUPA) Supervisor of the Year award for the Jeffrey Cheah School of Medicine and Health Sciences, along with the Outstanding Supervisor accolade across all Monash University Malaysia schools. Notably, he received the Pro-Vice Chancellor’s Commendation in 2020 for outstanding research. Dr. Shaikh’s impactful publications on epilepsy garnered recognition, including the JCSMHS 2019 Best Publication Award. His dedication to education was acknowledged with the Young Researcher Award and Young Teachers Award in 2019 from the Malaysian Society of Pharmacology and Physiology. 🏆👨🔬
Research Focus:
Dr. Mohd. Farooq Shaikh’s research focus revolves around neuropharmacology, with a particular emphasis on traumatic brain injuries (TBI), neuroinflammation, epilepsy, and cognitive dysfunction. His work spans various aspects of neurological disorders, investigating biomarkers like HMGB1 and exploring potential therapeutic targets. Notably, he delves into the impact of AMPA receptor GluA2 subunit defects on neurodevelopmental disorders and sheds light on the role of inflammation in epilepsy and neurobehavioral comorbidities. Dr. Shaikh’s contributions extend to neuroprotective interventions, such as the study of natural products in conditions like Alzheimer’s and Parkinson’s disease. 🧠🔬
Publication Top Notes:
-
HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction– Cited by 231 – (2018) 🧠🔬
-
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders – Cited by 178 – (2019) 🧠🧬
-
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s disease (AD): from risk factors to therapeutic targeting– Cited by 153 – (2020) 🧠👴
-
Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling – Cited by 144 – (2019) 🧠🚦
-
Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy – Cited by 117 – (2018) 🧠💊
-
Zebrafish: a versatile animal model for fertility research – Cited by 102 – (2016) 🐟👶
-
Zebrafish as a model for epilepsy-induced cognitive dysfunction: a pharmacological, biochemical and behavioral approach– Cited by 97 – (2017) 🐟🧠
-
Alcohol use disorder, neurodegeneration, Alzheimer’s and Parkinson’s disease: Interplay between oxidative stress, neuroimmune response and excitotoxicity – Cited by 81 – (2020) 🍷🧠
-
Amelioration of cognitive deficit by embelin in a scopolamine-induced Alzheimer’s disease-like condition in a rat model – Cited by 79 – (2018) 🐀🧠
-
High mobility group box 1 (HMGB 1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches – Cited by 70 – (2019) 🧠⚡